APA (7th ed.) Citation

Beksaç, M., Eikema, D., Koster, L., Hulin, C., Poiré, X., Hamladji, R., . . . McLornan, D. (2024). In the era of Bortezomib-based induction, intensification of Melphalan-based conditioning with Bortezomib does not improve survival outcomes in newly diagnosed multiple myeloma: A study from the chronic malignancies working party of the EBMT. Bone marrow transplantation, 59(4), . https://doi.org/10.1038/s41409-023-02160-8

Chicago Style (17th ed.) Citation

Beksaç, Meral, et al. "In the Era of Bortezomib-based Induction, Intensification of Melphalan-based Conditioning with Bortezomib Does Not Improve Survival Outcomes in Newly Diagnosed Multiple Myeloma: A Study from the Chronic Malignancies Working Party of the EBMT." Bone Marrow Transplantation 59, no. 4 (2024). https://doi.org/10.1038/s41409-023-02160-8.

MLA (9th ed.) Citation

Beksaç, Meral, et al. "In the Era of Bortezomib-based Induction, Intensification of Melphalan-based Conditioning with Bortezomib Does Not Improve Survival Outcomes in Newly Diagnosed Multiple Myeloma: A Study from the Chronic Malignancies Working Party of the EBMT." Bone Marrow Transplantation, vol. 59, no. 4, 2024, https://doi.org/10.1038/s41409-023-02160-8.